Difference between revisions of "2011 EHR Quality Measure Spec 0387"
Peterbodtke (talk | contribs) |
(Added a glossary link to Action~) |
||
| Line 50: | Line 50: | ||
'''DEVELOPMENT STATUS''' (Add details here) | '''DEVELOPMENT STATUS''' (Add details here) | ||
| − | '''ACTION ITEMS / NEXT STEPS''' (Add details here) | + | '''[[ACTION~|Action]] ITEMS / NEXT STEPS''' (Add details here) |
'''PREPARE CERTIFICATION DOCUMENTATION''' (Add details here) | '''PREPARE CERTIFICATION DOCUMENTATION''' (Add details here) | ||
'''OPEN ISSUES / QUESTIONS''' (Add details here) | '''OPEN ISSUES / QUESTIONS''' (Add details here) | ||
Latest revision as of 21:48, 29 July 2012
MEASURE # 0387
MEASURE TITLE Oncology Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer
MEASURE DESCRIPTION Percentage of female patients aged 18 years and older with Stage IC through IIIC, ER or PR positive breast cancer who were prescribed tamoxifen or aromatase inhibitor (AI) during the 12-month reporting period.
Documents for 2011 EHR-Based Reporting
SPREADSHEET NQF_Retooled_Measure_0387.xlsx
SPREADSHEET GOOGLE DOC URL (editable) http://spreadsheets.google.com/a/worldvista.org/ccc?key=0ArxIkIV4NePEdDVGdmJOck5yNEFqeDZZM0Z3VU1uQ2c&hl=en&authkey=CPOaxsEH
PDF FILE NAME NQF_HQMF_HumanReadable_0387.pdf
PDF FILE URL https://docs.google.com/fileview?id=1k5M1UTImcClPX2hgNXmuOukw_1jty5Ul2lYZK_H-OHGxw5PvY3mk933fCkKS&hl=en
REGARDING MULTIPLE NUMERATORS N/A
| TARGET DATE | SOLUTION DEVELOPERS | STATUS | SPEC DEVELOPER | NUMERATOR(s) | DENOMINATOR(s) |
|---|---|---|---|---|---|
| Phase II | TBD | N/A | AMA | 1 | 1 |
SOLUTION DESIGN / TECHNOLOGY (Add details here)
SOLUTION COMPONENTS (Add details here)
DEPENDENCIES (Add details here)
COMMENTS / NOTES (Add details here)
DEVELOPMENT STATUS (Add details here)
Action ITEMS / NEXT STEPS (Add details here)
PREPARE CERTIFICATION DOCUMENTATION (Add details here)
OPEN ISSUES / QUESTIONS (Add details here)
